Induction of RelB Participates in Endotoxin Tolerance

Barbara K. Yoza, Jean Y.-Q. Hu, Sue L. Cousart, Lolita M. Forrest and Charles E. McCall
J Immunol September 15, 2006, 177 (6) 4080-4085; DOI: https://doi.org/10.4049/jimmunol.177.6.4080

Abstract

Using a THP-1 human promonocyte model of endotoxin tolerance that simulates the sepsis leukocyte phenotype, we previously showed that tolerant cells remain responsive to LPS endotoxin with degradation of IκB in the cytosol and nuclear translocation and accumulation of p50 and p65 NF-κB transcription factors. Despite this, endotoxin-inducible NF-κB-dependent innate immunity genes, like IL-1β, remained transcriptionally unresponsive in the tolerant phenotype, similar to the endotoxin tolerance observed in sepsis patients. In this study, we examined this paradox and found that RelB, another member of the NF-κB family, is induced during the establishment of tolerance. RelB expression correlated with IL-1β repression, and sepsis patients showed increased RelB when compared with normal controls. Transient expression of RelB inhibited IL-1β in endotoxin-responsive cells. In the inverse experiment, small inhibitory RNAs decreased RelB expression in tolerant cells and restored endotoxin induction of IL-1β. When we examined tolerant cell extracts, we found transcriptionally inactive NF-κB p65/RelB heterodimers. Taken together, our findings demonstrate that RelB can repress proinflammatory gene expression, and suggest that RelB expression in sepsis patient blood leukocytes may play a role in the endotoxin-tolerant phenotype.

Human sepsis is associated with an immunosuppressed phenotype that involves both innate and adaptive immunity and that is associated with a poor clinical outcome (1). NF-κB plays an essential, albeit controversial role in sepsis and in the LPS-tolerant phenotype that occurs during sepsis (2, 3, 4, 5, 6). Although the expression of many NF-κB-dependent genes, like IL-1β and TNF-α, are repressed in leukocytes from patients with septic shock (1), several studies have demonstrated elevated levels of p65 in sepsis nuclei (6, 7). Indeed, elevated levels of p65, the transcription-activating subunit of NF-κB, correlate with poor outcomes in these patients (2, 3). Animal and tissue culture models also show increased nuclear p50 levels, and formation of p50 homodimers is promoted by some investigators as a mechanism for transcription repression during endotoxin tolerance (8, 9, 10). Other studies (11) find no such connection.

Several lines of evidence also revealed that down-regulation of NF-κB signaling pathways, for example IL-1R-associated kinase (IRAK)3 (12, 13, 14, 15, 16) and IκB kinase, may significantly impact LPS response in the tolerant phenotype (17, 18). These dysfunctions, characteristic of LPS tolerance, may have developed as a mechanism to fine-tune the balance between a pro- and anti-inflammatory response that would ensue from the initial encounter with an infectious agent (19, 20). Many studies have found that expression of some anti-inflammatory genes is sustained during sepsis and LPS tolerance, and the physiological consequence of this immunosuppressed state continues to be explored (21, 22, 23, 24, 25, 26).

We reported that cytosolic NF-κB activation occurs in the human LPS-tolerant phenotype, as evidenced by LPS-mediated IκB degradation (27), nuclear translocation of NF-κB p50 and p65, and formation of DNA-binding competent NF-κB complexes, as assessed by EMSAs (28). Two notable defects in LPS-mediated response were observed in tolerance when compared with normal cells. In examining LPS-dependent TLR4 signaling pathways, we found that IRAK1 was inactivated, degraded, and absent in tolerant cells (29, 30, 31). In examining LPS repression of the IL-1β gene, chromatin immunoprecipitation (ChIP) studies revealed that the chromatin structure at or near the IL-1β TATA box was altered and in a transcriptionally inactive state (32, 33). To further understand this latter phenomenon, we also found that p65 did not bind to the NF-κB site within the IL-1β promoter, although inducible and present in tolerant nuclei (32). This finding was in contrast to our findings that p65 NF-κB complexes could bind in EMSA (28) and highlights the differences in in vitro (EMSA) and in vivo (ChIP) DNA-binding assays.

In this study, we sought an explanation to the increased levels of p65 in the nucleus of tolerant cells and the inability of p65 to access the IL-1β promoter in vivo and activate transcription. We tested the hypothesis that RelB may be induced as a negative feedback mechanism for repressing NF-κB transcription during LPS tolerance. We find increased expression of RelB that is coincident with the establishment of LPS tolerance. Overexpression of RelB significantly reduces LPS-induced IL-1β expression in naive cells. We also show that decreased expression of RelB by RelB small interfering RNA (siRNA) can restore endotoxin induction of IL-1β expression in tolerant cells. Finally, we find that blood leukocytes from sepsis patients expressed RelB, whereas normal healthy controls did not. Taken together, our findings suggest that RelB expression, as a negative feedback, may provide a necessary and sufficient molecular mechanism involved in the repression of NF-κB-dependent innate immunity genes observed in LPS tolerance.

Materials and Methods

Cell culture and stimulation

THP-1 cells obtained from the American Type Culture Collection were maintained in RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 10 U/ml penicillin G, 10 μg/ml streptomycin, 2 mM l-glutamine, and 10% FCS (low LPS FCS; Sigma-Aldrich) at 37°C and 5% CO2 in a humidified incubator. LPS-tolerant THP-1 cells were made and are characterized in detail, as described previously (27). Briefly, THP-1 cells were rendered LPS tolerant by preincubation for 16 h with LPS (1.0 μg/ml Gram-negative LPS (Escherichia coli 0111:B4; Sigma-Aldrich)). Normal (no preincubation) and tolerant THP-1 cells were washed with FCS-free RPMI 1640 medium, then resuspended in FCS-supplemented RPMI 1640 medium at 1 × 106 cells/ml, and stimulated with LPS (1.0 μg/ml) for the times as indicated in the figure legends. Nonspecific and RelB siRNAs (Santa Cruz Biotechnology) were transfected using an AMAXA THP-1 transfection kit, according to the manufacturer’s protocol. pcDNA3-HA and HA-RelB (34) were gifts from G. Bren (Mayo Clinic, Rochester, MN). NF-κB p65 was provided by A. Baldwin (University of North Carolina, Chapel Hill, NC). Low passage number and log-phase cells were used for all experiments. All solutions were monitored routinely for LPS contamination by the Limulus amebocyte lysate assay (sensitivity <1 pg/ml).

Peripheral blood leukocyte, polymorphonuclear blood leukocyte (PMN), and PBMC isolation

The selection of patients was based on a modified criteria of Bone (35), as previously described (36). Using these criteria, 95% of patients reproducibly have reduced IL-1β production in response to LPS (23, 36). Patients enrolled in this study were positive for Gram-positive and/or Gram-negative sepsis. The patient without sepsis was a trauma patient with pulmonary contusion. Patients with known HIV infection, hematological malignancies affecting leukocyte counts, current cytotoxic chemotherapy, and high-dose glucocorticoid treatment were excluded. The Internal Review Board endorsed the study for Clinical Research associated with the General Clinical Research Center of the Medical Center. A venous or arterial heparinized blood sample (up to 30 ml) was drawn from patients within 1–4 days after the onset of sepsis or from normal healthy controls and immediately processed. PBL were isolated by Isolymph sedimentation (Gallard-Schlesinger), followed by centrifugation for 5 min at 200 × g at room temperature. The remaining erythrocytes were lysed in LPS-free H2O for 20 s before isotonicity was restored with 3.6% NaCl. Isolated PBL were washed and counted in PBS. PBL whole cell lysates were immediately prepared in SDS-Tris sample solubilization/loading buffer (reducing) and stored at −20°C until further use. PMN and PBMC were isolated, as previously described (23, 27). The proportions of PMN in PBL vary in sepsis (85–95%) when compared with normal (60–80%). In two patients, one without sepsis and one with sepsis, PBL were further separated into PMN and PBMC by a second centrifugation over 3 ml of Isolymph for 30 min at 400 × g. The PMN pellet and PBMC interface were washed and counted in PBS, and lysates were immediately prepared in SDS-Tris sample solubilization/loading buffer (reducing) and stored at −20°C until further use in Western blot analysis, as described below.

Immunoprecipitation and Western blot analysis

Whole cell and nuclear extracts (28) were prepared, using the protocols described previously. Whole cell and nuclear extract proteins (50 μg) were separated by SDS-PAGE and transferred to an Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad). RelB, B cell lymphoma protein 2 (Bcl-2), β-actin, IκB (α), agarose-conjugated p50 and p65 NF-κB Abs, and appropriate HRP-conjugated secondary Abs (Santa Cruz Biotechnology) were used to immunoprecipitate and/or visualize proteins using Western blot protocols, as specified by the manufacturer. Blots were stripped and reprobed with control Abs (Bcl-2, β-actin), as indicated. Protein levels on the blots were quantitated using ImageQuant software (Amersham Biosciences).

Real-time PCR analysis

Total RNA was isolated from 1 × 107 cells/condition using RNA STAT-60 (Tel-Test), according to the manufacturer’s instructions. cDNA was reverse transcribed in a final volume of 20 μl containing 1 μg of total RNA, 10× PCR buffer, 200 μM deoxynucleotides, 1 μM oligo(dT), 2 mM MgCl2, and 2.5 U of murine leukemia virus reverse transcriptase (Applied Biosystems) for 1 h at 42°C. IL-β mRNA was quantitated by real-time PCR using TaqMan methodology and an ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Real-time PCR were performed in 25 μl of a mixture containing 1 μl of cDNA (1 μg), 300 nM IL-1β primers, 100 nM FAM/TAMRA TaqMan probe, and 12.5 μl of TaqMan Universal PCR Master Mix, containing AmpliTaq Gold DNA polymerase, reaction buffer, and dNTP mix (Applied Biosystems). Results from at least three independent experiments were quantitated by continuous measurement during 40 cycles. All data were normalized to GAPDH quantitated in parallel samples (Applied Biosystems).

Statistical analysis

Statistical analysis of data is presented as the average of at least three independent experiments ± SEM. Analyses were performed after consultation with a statistician using Student’s t test to determine significant changes (p ≤ 0.05) using Microsoft Excel 2002 statistical analysis software, as indicated.

Results

RelB is expressed in LPS-tolerant cells

We first determined the time course of RelB expression in the THP-1 human promonocyte model of LPS tolerance. We found that LPS-tolerant cells express increased levels of RelB, as shown in Fig. 1⇓A. We next examined nuclear extracts for RelB expression and found low levels of RelB in normal cells that is increased in tolerant cell nuclei. Thus, the appearance and localization of RelB are consistent with a potential role in LPS tolerance. We also compared sepsis PBL with normal PBL (Fig. 1⇓B) and also found increased RelB in sepsis patients’ PBL, further supporting our hypothesis that RelB may mediate LPS tolerance. To further associate RelB expression with LPS tolerance, PMN and PBMC were isolated from two patients, without (Fig. 1⇓C, P4) and with sepsis (Fig. 1⇓C, P5). Consistent with our previous results, RelB was found only in the patient with sepsis.

FIGURE 1.
FIGURE 1.

RelB is expressed in LPS-tolerant cells. A, Normal and tolerant THP-1 cells were stimulated with LPS (1 μg/ml), and levels of RelB were determined in whole cell (WCE) and nuclear extracts (NE) by Western blot analysis, as described in Materials and Methods. B, PBL were isolated from normal healthy controls (C1, C2, C3) and sepsis patients (P1, P2, P3), and RelB levels were determined by Western blot. Bcl-2 and β-actin levels were used as immunoblot control Abs. Samples shown are representative of at least five independent observations. C, PBMC and PMN were isolated from two patients, one without (P4) and one with (P5) sepsis. RelB and β-actin levels were determined by Western blot.

Expression of RelB in normal cells mimics tolerance and inhibits IL-1β expression

We and others had observed that tolerant cells do not respond to LPS with an immediate and robust induction of proinflammatory genes. Paradoxically, we found that LPS-tolerant cells still showed LPS-stimulated IκB degradation and p50/p65 nuclear translocation, despite the continued repression of IL-1β expression. Our recent ChIP studies provided a partial explanation for this discrepancy, in which we found that p65 was unable to bind the IL-1β promoter in tolerant cells (32). Given the correlation between the appearance of RelB and transcription inhibition, we next tested the hypothesis that RelB mediated decreased expression of IL-1β. THP-1 cells were transfected with a human RelB expression vector (Bren and colleagues (34)) or empty vector (control). As shown in Fig. 2⇓A, cells transfected with RelB showed increased levels of RelB protein compared with cells transfected with the empty vector. Levels of transfected RelB were comparable to RelB protein levels in tolerant cells (Fig. 2⇓B). RelB-transfected or control cells were stimulated with LPS and IL-1β mRNA measured by real-time PCR at 1 and 3 h after stimulation. In these experiments (Fig. 2⇓C), we found that RelB expression decreased IL-1β mRNA levels after LPS stimulation. Control cells (empty vector) showed the rapid and transient expression of IL-1β mRNA that is typical of the immune response to LPS. In contrast, RelB-expressing cells showed a significant decrease in IL-1β expression that is characteristic of LPS tolerance. Thus, this experiment supports the hypothesis that RelB can repress LPS-induced expression of IL-1β and is consistent with a role in the LPS-tolerant phenotype. We further examined whether expression of NF-κB p65 might overcome the LPS tolerance induced by RelB. As shown in Fig. 2⇓D, p65 was able to overcome RelB-mediated suppression.

FIGURE 2.
FIGURE 2.

RelB expressed in normal cells mimics tolerance and inhibits IL-1β expression. A, A RelB expression vector (HA-RelB) was transfected into THP-1 cells, as described in Materials and Methods. The empty vector was used as a control. RelB levels in expression vector- and empty vector-transfected cells were assessed by immunoblot, as shown on the right. RelB levels in tolerant THP-1 cells are shown on the left for comparison. B, RelB protein levels in transfected cells were quantitated on Western blot, as described in Materials and Methods. Increased RelB levels in transfected cells are the average of two experiments ± SEM; RelB levels in normal and tolerant cells (nontransfected) are shown for comparison. C, RelB (▪)- and empty vector (□)-transfected cells were stimulated with LPS and total RNA isolated at various times after stimulation. IL-1β and GAPDH mRNA were measured by real-time PCR, as described in Materials and Methods. Relative IL-1β mRNA levels are normalized to GAPDH mRNA and are shown as the average (±SEM) for each of three independent experiments. D, RelB (▪)-, empty vector (□)-, or RelB + NF-κB p65 (▩)-transfected cells were stimulated with LPS and total RNA isolated at various times after stimulation. IL-1β and GAPDH mRNA were measured by real-time PCR, as described in Materials and Methods. Relative IL-1β mRNA levels are normalized to GAPDH mRNA in each sample. Data shown are representative of two independent experiments, with mRNA measured in duplicate for each experiment.

Gene silencing of RelB by siRNA can reverse LPS tolerance

The introduction of siRNA as a molecular tool has developed into a powerful technique for selective gene silencing (reviewed in Ref. 37). We used RelB-specific siRNA to test whether the knockdown of RelB protein levels in tolerant cells could restore LPS responsiveness and increase IL-1β mRNA. As shown in Fig. 3⇓, introduction of RelB siRNA significantly reduced RelB protein levels in tolerant cells. This decrease persisted even with LPS stimulation. In contrast, control siRNA still showed the high levels of RelB associated with LPS tolerance.

FIGURE 3.
FIGURE 3.

Gene silencing of RelB by siRNA can significantly decrease RelB levels. RelB levels in tolerant cells in the presence of nonspecific or control (ctrl siRNA) or RelB-specific siRNAs (RelB siRNA) were assessed by Western blot. A, Shows that RelB levels are decreased in the tolerant cells by RelB siRNA. IκB and p65 protein levels in RelB knockdown cell are unchanged, as shown below. Western blots were stripped and reprobed with β-actin as an immunoblot control. B, Quantitation of RelB levels from three separate experiments shows a significant decrease in RelB levels in tolerant cells by RelB siRNA (p = 0.003 for RelB siRNA compared with control siRNA; p = 0.02 for RelB siRNA + LPS compared with control siRNA + LPS).

Given the demonstration of significantly reduced RelB levels by RelB-specific siRNA, we further asked whether this gene silencing could restore LPS response and induce IL-1β expression, i.e., reverse the LPS-tolerant phenotype. Fig. 4⇓A shows the decreased LPS response to induction of IL-1β that is a salient feature of LPS-tolerant cells (compare control ±LPS with tolerant ±LPS). We found that introduction of control siRNA still showed this repressed LPS response and decreased IL-1β expression in tolerant cells (Fig. 4⇓B). In contrast, RelB siRNA was able to reverse the repression and near normal levels of IL-1β mRNA were induced by LPS in RelB knockdown tolerant cells (Fig. 4⇓C). These data strongly support a role for RelB in mediating LPS tolerance.

FIGURE 4.
FIGURE 4.

Gene silencing of RelB by siRNA can reverse LPS tolerance. Normal (N) and tolerant (T) THP-1 cells were stimulated with (+) or without (−) LPS, and IL-1β mRNA levels were measured by real-time PCR, as described in Materials and Methods. A, Shows IL-1β mRNA levels in cells not transfected for comparison; B and C, show IL-1β mRNA levels in cells transfected with control siRNA (nonspecific) or RelB siRNA (specific), respectively. Data shown are the results of three independent experiments, with RNA levels measured in duplicate and relative to GAPDH mRNA for each sample. Significant differences (∗) are observed between normal and tolerant stimulated IL-1β mRNA levels in nontransfected cells (A, compare N+ with T+; p = 0.002) or control siRNA cells (B, compare N+ with T+; p = 0.03). Normal and tolerant cells transfected with RelB siRNA (C, compare N+ with T+) show comparable levels of IL-1β in response to LPS.

RelB inhibition of LPS-stimulated immune response

Studies in relb−/− mice implicate an important role for RelB in limiting multiorgan inflammation and showed that RelB is a key transcriptional regulator in suppressing proinflammatory cytokine expression (38). In particular, RelB was implicated in delimiting the LPS response in relb−/− fibroblasts and, in the absence of RelB, IL-1β was overexpressed (39). This study revealed that relb−/− mice have lowered levels of IκB and, consequently, augmented NF-κB activation and enhanced expression of a number of proinflammatory cytokines and chemokines. As we had previously implicated IκB as a labile transcription inhibitor in LPS tolerance (27), we first tested whether RelB knockdown (i.e., RelB siRNA-transfected) cells, like relb−/− cells, had lowered levels of IκB, and whether this decrease could provide a mechanism for enhanced IL-1β and the reversal of tolerance in knockdown cells. However, as shown in Fig. 3⇑A, we did not observe a decrease in IκB levels in RelB knockdown cells.

Alternatively, RelB has also been shown to have differential transcription activity dependent on interaction with variable cofactors. A number of NF-κB (34, 40) and non-NF-κB proteins (41, 42) have been implicated in this role. In particular, several studies suggest that p65/RelB heterodimers are unable to bind DNA and, as such, form transcriptionally inactive complexes (43, 44). As shown in Fig. 5⇓, we examined immunoprecipitates from tolerant THP-1 cells for formation of p65 and RelB complexes. In these experiments, we found RelB associated with p65, suggesting that repressed transcription of IL-1β observed in tolerant cells is due, at least in part, to inactive NF-κB.

FIGURE 5.
FIGURE 5.

RelB inhibition of LPS-stimulated immune response. Normal (NOR) and tolerant (TOL) THP-1 cells were unstimulated (0) or stimulated with LPS (0.5 or 1 h), as indicated in the figure. Whole cell (WCE) and nuclear (NE) extracts were prepared, and p65 immunoprecipitates (IP) were examined by Western blot for the presence of RelB. Whole cell and nuclear extracts from tolerant cells show coprecipitation of inactive p65/RelB, consistent with the repressed NF-κB transcription observed in LPS tolerance.

Discussion

RelB as a mediator of immunosuppression

In this study, we show a novel role for RelB in the transcription-repressed phenotype of LPS-tolerant cells. We found that RelB expression is induced as part of a primary NF-κB response to inflammation, which includes IκB degradation, NF-κB nuclear translocation, and transcription of proinflammatory genes as immediate early responses. Increased levels of RelB were observed after this initial wave of proinflammatory response and are consistent with the observation that induction of RelB itself is NF-κB dependent (45). Subsequent to the initial response is the LPS-tolerant refractory state. We had shown previously that IκB degradation and NF-κB nuclear translocation remained viable in LPS tolerance, but that the transcription activation of proinflammatory genes, like IL-1β, was repressed (28). Using ChIP assays, we further showed that LPS-tolerant cells do not bind p65 at the IL-1β promoter despite increased p65 in the nucleus, in contrast to LPS-responsive cells that show a rapid and transient p65 binding to IL-1β promoter (32). In the study presented in this work, we show that RelB inhibits IL-1β expression, suggesting that this regulatory pathway may function as a negative feedback loop in the immunosuppression that is found in association with septic shock (19, 20), in which many acute proinflammatory genes become hyporesponsive to inflammatory stimuli. Other proteins, such as A20 and IRAK-M, are advocated as potential negative feedback loops in LPS tolerance (46), but these negative regulators are implicate in disrupting cytosolic activation of NF-κB. Tolerant cells do not show reduced IκBa levels, consistent with a distinct role for RelB in tolerant cells that is independent of IκB.

Our present studies suggest that immunosuppression is a result, at least in part, of the sequestration of p65 by RelB and the formation of transcription inactive complexes that are unable to activate proinflammatory genes in LPS-tolerant cells. These inactive complexes are unable to bind the IL-1β promoter and activate transcription, thus providing a reasonable explanation for our ChIP results that showed disruption of p65 binding in LPS-tolerant cells. RelB induction in tolerant cells may also suppress other acute proinflammatory genes, such as TNF-α, during sepsis and LPS tolerance; this hypothesis remains to be tested. However, the LPS-tolerant phenotype found in sepsis blood leukocytes and cell models is associated with the disruption of other transcription factors unrelated to the NF-κB family (28). Further studies will be needed to identify what, if any, role RelB may play in the suppression of other transcription factors and LPS-tolerant genes. The complex phenotype of sepsis and LPS tolerance is multifactorial and involves the interaction of many regulatory pathways (46, 47).

Regulation of RelB

The canonical NF-κB pathway is largely dependent on IκB kinase β to promote phosphorylation and degradation of IκB and translocation of NF-κB to the nucleus (48). More recently, an alternative pathway to NF-κB activation has been proposed, in which IκB kinase α and NF-κB-inducing kinase play a more essential role and in which nuclear localization of RelB regulates the expression of a subset of chemokines involved in spleen development (49). In addition to nuclear localization, RelB is regulated by phosphorylation (50) and dimerization (49, 51). The roles that these pathways may play in the establishment of the tolerant phenotype remain to be elucidated.

The LPS-induced RelB, acting as a negative feedback loop to curb an overwhelming and potentially devastating inflammatory response, can be implicated in the sustained LPS-tolerant phenotype that is observed during the course of sepsis (3, 4, 5, 6, 7, 8). Consistent with this model, RelB was constitutively elevated in the sepsis patient leukocytes that we examined. More detailed temporal studies of sepsis patients will be required to assess whether RelB expression correlates with the onset of the immunosuppressed phenotype and whether RelB is lost when the disease state is resolved and immunoresponsiveness is restored. Sepsis is a complicated and not very well-understood syndrome that will require further investigations to examine the participation of RelB in this immune response.

RelB as a mediator of innate and adaptive immunity

Although mechanisms of NF-κB activation are relatively well understood, the specificity and diversity of transcription control imparted by the activity of this family of proteins continue to be discovered. Given the central role these proteins play in inflammatory processes, we and others (for a review, see Ref. 52) have focused on NF-κB proteins in immune response and disease. In particular, we have studied the immunosuppressed state associated with LPS tolerance that is related to clinical immunosuppressed state observed in sepsis. Our finding of a role for RelB in immunosuppression is consistent with the experimental findings in relB(−/−) mice that showed increased expression of proinflammatory cytokines and an increased susceptibility to opportunistic infection (53). Relb-deficient mice also show a generalized multiorgan inflammation (54, 55). More recently, it has been demonstrated that RelB plays a unique role in the transition from immediate early innate immune responses to that of more prolonged adaptive immune responses. In particular, RelB is thought to be a critical regulator of dendritic cell (DC) maturation that assures a functional transition from innate to adaptive immunity (56). RelB-deficient mice show a dramatic decrease in thymic and splenic DCs and are impaired in Ag-presenting function and cellular immunity (57). In this study, our results extend this regulatory role and suggest that RelB is essential to an immune response program. Within innate immunity, RelB may down-regulate acute inflammation; as an activator, RelB facilitates the maturation of DCs that are necessary in Ag presentation, T cell activation, and acquisition of adaptive immunity (58).

Acknowledgments

We acknowledge the gifts of RelB (G. Bren) and p65 plasmids (A. Baldwin); the assistance of J. Smith, A. Howard, and D. Hite with patient samples; and the thoughtful discussions with A. Baldwin in the preparation of this manuscript.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by National Institutes of Health Grant AI-09169 (to C.E.M.) and MO1-RR007122 to the Wake Forest University Medical Center General Clinical Research Center.

  • ↵2 Address correspondence and reprint requests to Dr. Barbara K. Yoza, Wake Forest University School of Medicine, Department of Surgery, Medical Center Boulevard, Winston-Salem, NC 27157. E-mail address: byoza{at}wfubmc.edu

  • ↵3 Abbreviations used in this paper: IRAK, IL-1R-associated kinase; ChIP, chromatin immunoprecipitation; DC, dendritic cell; PMN, polymorphonuclear blood leukocyte; siRNA, small interfering RNA.

  • Received March 22, 2006.
  • Accepted July 5, 2006.

References

  1. ↵
    West, M. A., W. Heagy. 2002. Endotoxin tolerance: a review. Crit. Care Med. 30: S64-S73.
    OpenUrlCrossRefPubMed
  2. ↵
    Arnalich, F., E. Garcia-Palomero, J. Lopez, M. Jimenez, R. Madero, J. Renart, J. J. Vazquez, C. Montiel. 2000. Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis. Infect. Immun. 68: 1942-1945.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Bohrer, H., F. Qiu, T. Zimmermann, Y. Zhang, T. Jllmer, D. Mannel, B. W. Bottiger, D. M. Stern, R. Waldherr, H. D. Saeger, et al 1997. Role of NFκB in the mortality of sepsis. J. Clin. Invest. 100: 972-985.
    OpenUrlCrossRefPubMed
  4. ↵
    Bohrer, H., P. P. Nawroth. 1998. Nuclear factor κB: a new therapeutic approach?. Intensive Care Med. 24: 1129-1130.
    OpenUrlCrossRefPubMed
  5. ↵
    Browder, W., T. Ha, L. Chuanfu, J. H. Kalbfleisch, D. A. Ferguson, Jr, D. L. Williams. 1999. Early activation of pulmonary nuclear factor κB and nuclear factor interleukin-6 in polymicrobial sepsis. J. Trauma 46: 590-596.
    OpenUrlCrossRefPubMed
  6. ↵
    Yang, R. C., H. W. Chen, T. S. Lu, C. Hsu. 2000. Potential protective effect of NF-κB activity on the polymicrobial sepsis of rats preconditioning heat shock treatment. Clin. Chim. Acta 302: 11-22.
    OpenUrlCrossRefPubMed
  7. ↵
    Foulds, S., C. Galustian, A. O. Mansfield, M. Schachter. 2001. Transcription factor NF κB expression and postsurgical organ dysfunction. Ann. Surg. 233: 70-78.
    OpenUrlCrossRefPubMed
  8. ↵
    Adib-Conquy, M., C. Adrie, P. Moine, K. Asehnoune, C. Fitting, M. R. Pinsky, J. F. Dhainaut, J. M. Cavaillon. 2000. NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am. J. Respir. Crit. Care Med. 162: 1877-1883.
    OpenUrlCrossRefPubMed
  9. ↵
    Bohuslav, J., V. V. Kravchenko, G. C. Parry, J. H. Erlich, S. Gerondakis, N. Mackman, R. J. Ulevitch. 1998. Regulation of an essential innate immune response by the p50 subunit of NF-κB. J. Clin. Invest. 102: 1645-1652.
    OpenUrlCrossRefPubMed
  10. ↵
    Ziegler-Heitbrock, H. W.. 1995. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 45: 13-26.
    OpenUrlPubMed
  11. ↵
    Wysocka, M., S. Robertson, H. Riemann, J. Caamano, C. Hunter, A. Mackiewicz, L. J. Montaner, G. Trinchieri, C. L. Karp. 2001. IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J. Immunol. 166: 7504-7513.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Fan, H., J. A. Cook. 2004. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10: 71-84.
    OpenUrlCrossRefPubMed
  13. ↵
    Kobayashi, K., L. D. Hernandez, J. E. Galan, C. A. Janeway, Jr, R. Medzhitov, R. A. Flavell. 2002. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202.
    OpenUrlCrossRefPubMed
  14. ↵
    Medvedev, A. E., A. Lentschat, L. M. Wahl, D. T. Golenbock, S. N. Vogel. 2002. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J. Immunol. 169: 5209-5216.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Nakayama, K., S. Okugawa, S. Yanagimoto, T. Kitazawa, K. Tsukada, M. Kawada, S. Kimura, K. Hirai, Y. Takagaki, Y. Ota. 2004. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J. Biol. Chem. 279: 6629-6634.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Yamashina, S., M. D. Wheeler, I. Rusyn, K. Ikejima, N. Sato, R. G. Thurman. 2000. Tolerance and sensitization to endotoxin in Kupffer cells caused by acute ethanol involve interleukin-1 receptor-associated kinase. Biochem. Biophys. Res. Commun. 277: 686-690.
    OpenUrlCrossRefPubMed
  17. ↵
    Dobrovolskaia, M. A., A. E. Medvedev, K. E. Thomas, N. Cuesta, V. Toshchakov, T. Ren, M. J. Cody, S. M. Michalek, N. R. Rice, S. N. Vogel. 2003. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR “homotolerance” versus “heterotolerance” on NF-κB signaling pathway components. J. Immunol. 170: 508-519.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Christman, J. W., L. H. Lancaster, T. S. Blackwell. 1998. Nuclear factor κB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 24: 1131-1138.
    OpenUrlCrossRefPubMed
  19. ↵
    Munford, R. S., J. Pugin. 2001. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 163: 316-321.
    OpenUrlCrossRefPubMed
  20. ↵
    Pinsky, M. R.. 2001. Sepsis: a pro- and anti-inflammatory disequilibrium syndrome. Contrib. Nephrol. 132: 354-366.
    OpenUrlCrossRefPubMed
  21. ↵
    Cobb, J. P., J. M. Laramie, G. D. Stormo, J. J. Morrissey, W. D. Shannon, Y. Qiu, I. E. Karl, T. G. Buchman, R. S. Hotchkiss. 2002. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays. Crit. Care Med. 30: 2711-2721.
    OpenUrlCrossRefPubMed
  22. ↵
    Hotchkiss, R. S., I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
    OpenUrlCrossRefPubMed
  23. ↵
    Mueller, L. P., B. K. Yoza, K. Neuhaus, C. S. Loeser, S. Cousart, M. C. Chang, J. W. Meredith, L. Li, C. E. McCall. 2001. Endotoxin-adapted septic shock leukocytes selectively alter production of sIL-1RA and IL-1β. Shock 16: 430-437.
    OpenUrlCrossRefPubMed
  24. ↵
    Giri, J. G., J. Wells, S. K. Dower, C. E. McCall, R. N. Guzman, J. Slack, T. A. Bird, K. Shanebeck, K. H. Grabstein, J. E. Sims. 1994. Elevated levels of shed type II IL-1 receptor in sepsis: potential role for type II receptor in regulation of IL-1 responses. J. Immunol. 153: 5802-5809.
    OpenUrlAbstract
  25. ↵
    Learn, C. A., S. B. Mizel, C. E. McCall. 2000. mRNA and protein stability regulate the differential expression of pro- and anti-inflammatory genes in endotoxin-tolerant THP-1 cells. J. Biol. Chem. 275: 12185-12193.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H. E. Harris, S. M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, et al 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101: 296-301.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    LaRue, K. E., C. E. McCall. 1994. A labile transcriptional repressor modulates endotoxin tolerance. J. Exp. Med. 180: 2269-2275.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Yoza, B. K., J. Y. Hu, S. L. Cousart, C. E. McCall. 2000. Endotoxin inducible transcription is repressed in endotoxin tolerant cells. Shock 13: 236-243.
    OpenUrlCrossRefPubMed
  29. ↵
    Jacinto, R., T. Hartung, C. McCall, L. Li. 2002. Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor-associated kinase. J. Immunol. 168: 6136-6141.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Li, L., S. Cousart, J. Hu, C. E. McCall. 2000. Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J. Biol. Chem. 275: 23340-23345.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Li, L., R. Jacinto, B. Yoza, C. E. McCall. 2003. Distinct post-receptor alterations generate gene- and signal-selective adaptation and cross-adaptation of TLR4 and TLR2 in human leukocytes. J. Endotoxin Res. 9: 39-44.
    OpenUrlCrossRefPubMed
  32. ↵
    Chan, C., L. Li, C. E. McCall, B. K. Yoza. 2005. Endotoxin tolerance disrupts chromatin remodeling and NF-κB transactivation at the IL-1β promoter. J. Immunol. 175: 461-468.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Yoza, B. K., J. Y. Hu, C. E. McCall. 2002. Inhibition of histone deacetylation enhances endotoxin-stimulated transcription but does not reverse endotoxin tolerance. J. Endotoxin Res. 8: 109-114.
    OpenUrlCrossRefPubMed
  34. ↵
    Solan, N. J., H. Miyoshi, E. M. Carmona, G. D. Bren, C. V. Paya. 2002. RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem. 277: 1405-1418.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Bone, R. C.. 1996. The sepsis syndrome: definition and general approach to management. Clin. Chest Med. 17: 175-181.
    OpenUrlCrossRefPubMed
  36. ↵
    McCall, C. E., L. M. Grosso-Wilmoth, K. LaRue, R. N. Guzman, S. L. Cousart. 1993. Tolerance to endotoxin-induced expression of the interleukin-1β gene in blood neutrophils of humans with the sepsis syndrome. J. Clin. Invest. 91: 853-861.
    OpenUrlCrossRefPubMed
  37. ↵
    Filipowicz, W.. 2005. RNAi: the nuts and bolts of the RISC machine. Cell 122: 17-20.
    OpenUrlCrossRefPubMed
  38. ↵
    Xia, Y., M. E. Pauza, L. Feng, D. Lo. 1997. RelB regulation of chemokine expression modulates local inflammation. Am. J. Pathol. 151: 375-387.
    OpenUrlPubMed
  39. ↵
    Xia, Y., S. Chen, Y. Wang, N. Mackman, G. Ku, D. Lo, L. Feng. 1999. RelB modulation of IκBα stability as a mechanism of transcription suppression of interleukin-1α (IL-1α), IL-1β, and tumor necrosis factor α in fibroblasts. Mol. Cell. Biol. 19: 7688-7696.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Derudder, E., E. Dejardin, L. L. Pritchard, D. R. Green, M. Korner, V. Baud. 2003. RelB/p50 dimers are differentially regulated by tumor necrosis factor-α and lymphotoxin-β receptor activation: critical roles for p100. J. Biol. Chem. 278: 23278-23284.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Dong, X., T. Craig, N. Xing, L. A. Bachman, C. V. Paya, F. Weih, D. J. McKean, R. Kumar, M. D. Griffin. 2003. Direct transcriptional regulation of RelB by 1α,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 278: 49378-49385.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Dong, X., W. Lutz, T. M. Schroeder, L. A. Bachman, J. J. Westendorf, R. Kumar, M. D. Griffin. 2005. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc. Natl. Acad. Sci. USA 102: 16007-16012.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Jacque, E., T. Tchenio, G. Piton, P. H. Romeo, V. Baud. 2005. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc. Natl. Acad. Sci. USA 102: 14635-14640.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Marienfeld, R., M. J. May, I. Berberich, E. Serfling, S. Ghosh, M. Neumann. 2003. RelB forms transcriptionally inactive complexes with RelA/p65. J. Biol. Chem. 278: 19852-19860.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Bren, G. D., N. J. Solan, H. Miyoshi, K. N. Pennington, L. J. Pobst, C. V. Paya. 2001. Transcription of the RelB gene is regulated by NF-κB. Oncogene 20: 7722-7733.
    OpenUrlCrossRefPubMed
  46. ↵
    Han, J., R. J. Ulevitch. 2005. Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6: 1198-1205.
    OpenUrlCrossRefPubMed
  47. ↵
    Palsson-McDermott, E. M., L. A. O’Neill. 2004. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113: 153-162.
    OpenUrlCrossRefPubMed
  48. ↵
    Karin, M., Y. Ben Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18: 621-663.
    OpenUrlCrossRefPubMed
  49. ↵
    Bonizzi, G., M. Bebien, D. C. Otero, K. E. Johnson-Vroom, Y. Cao, D. Vu, A. G. Jegga, B. J. Aronow, G. Ghosh, R. C. Rickert, M. Karin. 2004. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23: 4202-4210.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Maier, H. J., R. Marienfeld, T. Wirth, B. Baumann. 2003. Critical role of RelB serine 368 for dimerization and p100 stabilization. J. Biol. Chem. 278: 39242-39250.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Saccani, S., S. Pantano, G. Natoli. 2003. Modulation of NF-κB activity by exchange of dimers. Mol. Cell 11: 1563-1574.
    OpenUrlCrossRefPubMed
  52. ↵
    Baldwin, A. S.. 2001. The transcription factor NF-κB and human disease. J. Clin. Invest. 107: 3-6.
    OpenUrlCrossRefPubMed
  53. ↵
    Weih, F., G. Warr, H. Yang, R. Bravo. 1997. Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 158: 5211-5218.
    OpenUrlAbstract
  54. ↵
    Weih, F., S. K. Durham, D. S. Barton, W. C. Sha, D. Baltimore, R. Bravo. 1996. Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. J. Immunol. 157: 3974-3979.
    OpenUrlAbstract
  55. ↵
    Ryseck, R. P., F. Weih, D. Carrasco, R. Bravo. 1996. RelB, a member of the Rel/NF-κB family of transcription factors. Braz. J. Med. Biol. Res. 29: 895-903.
    OpenUrlPubMed
  56. ↵
    Zanetti, M., P. Castiglioni, S. Schoenberger, M. Gerloni. 2003. The role of relB in regulating the adaptive immune response. Ann. NY Acad. Sci. 987: 249-257.
    OpenUrlCrossRefPubMed
  57. ↵
    Wu, L., A. D’Amico, K. D. Winkel, M. Suter, D. Lo, K. Shortman. 1998. RelB is essential for the development of myeloid-related CD8α− dendritic cells but not of lymphoid-related CD8α+ dendritic cells. Immunity 9: 839-847.
    OpenUrlCrossRefPubMed
  58. ↵
    Cejas, P. J., L. M. Carlson, D. Kolonias, J. Zhang, I. Lindner, D. D. Billadeau, L. H. Boise, K. P. Lee. 2005. Regulation of RelB expression during the initiation of dendritic cell differentiation. Mol. Cell. Biol. 25: 7900-7916.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section